These downstream effects of TOP2A expression, along with the enhanced expression of TOP2A observed in metastatic luminal breast cancer and prostate cancer, indicate a potential role in all five stages of the metastatic cascade [88–91] (Table 2). The gene discussed is TOP2A; the disease is prostate cancer.